Hemaros Tablets: Nutritional Support for Iron Deficiency in Pregnant women

Abstract

Anemia in pregnancy is defined by the World Health Organization as hemoglobin levels of ≤ 11 g/dl. Globally, a prevalence rate

of 38% was estimated by the World Health Organization for pregnant women. To assess the safety, efficacy, tolerability of oral

ferrous bis-glycinate in pregnant women in the treatment of iron deficiency anemia (IDA)16. Ferrous bisglycinate is an iron amino

acid chelate. It is formed by reaction of ferrous iron with two molecules of the amino acid glycine by a covalent bound in a

process called chelation. Ferrous bisglycinate is claimed to have better patient compliance because of fewer gastrointestinal tract

side effects1 . During pregnancy, more iron is needed primarily to supply the growing fetus and placenta and to increase the

maternal red cell mass. Hemaros™ is containing of ferrous bisglycinate which very effective for iron supplementation for iron

deficiency anemia IDA2 . Pregnant women with second trimester IDA could be supplied with ferrous bis-glycinate which is more

efficient in increasing HB level. Moreover, it has tolerable adverse effects and high compliance than ferrous glycine sulfate.